Health> Vol.5 No.5A, May 2013

Gemtuzumab ozogamicin in the treatment of adult acute myeloid leukemia

ABSTRACT

Gemtuzumab ozogamicin (GO) is a humanized anti-CD33 monoclonal antibody conjugated to a derivative of an antitumor antibiotic, calicheamicin. GO was approved for the treatment of relapsed acute myeloid leukemia (AML) in the United States (US) in 2000. However, GO was withdrawn from the US market in June 2010, because a large-scale clinical trial failed to show additive or synergistic effects with conventional chemotherapy for newly diagnosed AML. GO is currently available only in Japan. However, several large clinical studies have demonstrated beneficial effects of GO when added to chemotherapy for AML in recent years; therefore, reconsideration of GO availability is gaining attention. Therefore, the role and efficacy of GO as monotherapy or in combination therapy for de novo or relapsed AML should be positively investigated.

KEYWORDS


Cite this paper

Tsunemine, H. and Takahashi, T. (2013) Gemtuzumab ozogamicin in the treatment of adult acute myeloid leukemia. Health, 5, 8-16. doi: 10.4236/health.2013.55A002.

References

[1] Lowenberg, B., Downing, J.R. and Burnett, A. (1999) Acute myeloid leukemia. New England Journal of Medicine, 341, 1051-1062. doi:10.1056/NEJM199909303411407
[2] Brincker, H. (1985) Estimate of overall treatment results in acute nonlymphocytic leukemia based on age-specific rates of incidence and of complete remission. Cancer Treatment Report, 69, 5-11.
[3] Burnett, A.K., Hills, R.K., Milligan, D.W., Goldstone, A.H., Prentice, A.G., McMullin, M.F., Duncombe, A., Gibson, B. and Wheatley, K. (2011) Attempts to optimize induction and consolidation treatment in acute myeloid leukemia: Results of the MRC AML12 trial. Journal of Clinical Oncology, 28, 586-595. doi:10.1200/JCO.2009.22.9088
[4] Fernandez, H.F., Sun, Z., Yao, X., Litzow, M.R., Luger, S.M., Paietta, E.M., Racevskis, J., Dewald, G.W., Ketterling, R.P., Bennett, J.M., Rowe, J.M., Lazarus, H.M. and Tallman, M.S. (2009) Anthracycline dose intensification in acute myeloid leukemia. New England Journal of Medicine, 361, 1249-1259. doi:10.1056/NEJMoa0904544
[5] Mandelli, F., Vignetti, M., Suciu, S., Stasi, R., Petti, M.C., Meloni, G., Muus, P., Marmont, F., Marie, J.P., Labar, B., Thomas, X., Di Raimondo, F., Willemze, R., Liso, V., Ferrara, F., Baila, L., Fazi, P., Zittoun, R., Amadori, S. and de Witte, T. (2009) Daunorubicin versus mitoxantrone versus idarubicin as induction and consolidation chemotherapy for adults with acute myeloid leukemia: The EORTC and GIMEMA Groups Study AML-10. Journal of Clinical Oncology, 27, 5397-5403. doi:10.1200/JCO.2008.20.6490
[6] Goldstone, A.H., Burnett, A.K., Wheatley, K., Smith, A.G., Hutchinson, R.M. and Clark, R.E. (2001) Attempts to improve treatment outcomes in acute myeloid leukemia (AML) in older patients: the results of the United Kingdom Medical Research Council AML11 trial. Blood, 98, 1302-1311. doi:10.1182/blood.V98.5.1302
[7] Burnett, A.K., Hills, R.K., Green, C., Jenkinson, S., Koo, K., Patel, Y., Guy, C., Gilkes, A., Milligan, D.W., Goldstone, A.H., Prentice, A.G., Wheatley, K., Linch, D.C. and Gale, R.E. (2010) The impact on outcome of the addition of alltrans retinoic acid to intensive chemotherapy in younger patients with nonacute promyelocytic acute myeloid leukemia: Overall results and results in genotypic subgroups defined by mutations in NPM1, FLT3, and CEBPA. Blood, 115, 948-956. doi:10.1182/blood-2009-08-236588
[8] Buchner, T., Berdel, W.E., Haferlach, C., Haferlach, T., Schnittger, S., Muller-Tidow, C., Braess, J., Spiekermann, K., Kienast, J., Staib, P., Grüneisen, A., Kern, W., Reichle, A., Maschmeyer, G., Aul, C., Lengfelder, E., Sauerland, M.C., Heinecke, A., Wörmann, B. and Hiddemann, W. (2009) Age-related risk profile and chemotherapy dose response in acute myeloid leukemia: A study by the German Acute Myeloid Leukemia Cooperative Group. Journal of Clinical Oncology, 27, 61-69. doi:10.1200/JCO.2007.15.4245
[9] Hamann, P.R., Hinman, L.M., Hollander, I., Beyer, C.F., Lindh, D., Holcomb, R., Hallett, W., Tsou, H.R., Upeslacis, J., Shochat, D., Mountain, A., Flowers, D.A. and Bernstein, I. (2002) Gemtuzumab ozogamicin, a potent and selective anti-CD33 antibody-calicheamicin conjugate for treatment of acute myeloid leukemia. Bioconjugate Chemistry, 13, 47-58. doi:10.1021/bc010021y
[10] Dinndorf, P.A., Andrews, R.G., Benjamin, D., Ridgway, D., Wolff, L. and Bernstein, I.D. (1986) Expression of normal myeloid-associated antigens by acute leukemia cells. Blood, 67, 1048-1053.
[11] Ikemoto, N., Kumar, R.A., Ling, T.T., Ellestad, G.A., Danishefsky, S.J. and Patel, D.J. (1995) Calicheamicin-DNA complexes: Warhead alignment and saccharide recognition of the minor groove. Proceedings of the National Academy of Sciences of the USA, 92, 10506-10510. doi:10.1073/pnas.92.23.10506
[12] Sievers, E.L., Larson, R.A., Stadtmauer, E.A., Estey, E., Lowenberg, B., Dombret, H., Karanes, C., Theobald, M., Bennett, J.M., Sherman, M.L., et al. (2001) Efficacy and safety of gemtuzumab ozogamicin in patients with CD33-positive acute myeloid leukemia in first relapse. Journal of Clinical Oncology, 19, 3244-3254.
[13] Larson, R.A., Sievers, E.L., Stadtmauer, E.A., Lowenberg, B., Estey, E.H., Dombret, H., Theobald, M., Voliotis, D., Bennett, J.M., Richie, M., et al. (2005) Final report of the efficacy and safety of gemtuzumab ozogamicin (Mylotarg) in patients with CD33-positive acute myeloid leukemia in first recurrence. Cancer, 104, 1442-1452. doi:10.1002/cncr.21326
[14] Kobayashi, Y., Tobinai, K., Takeshita, A., Naito, K., Asai, O., Dobashi, N., Furusawa, S., Saito, K., Mitani, K., Morishima, Y., et al. (2009) Phase I/II study of humanized anti-CD33 antibody conjugated with calicheamicin, gemtuzumab ozogamicin, in relapsed or refractory acute myeloid leukemia: final results of Japanese multicenter cooperative study. International Journal of Hematology, 89, 460-469. doi:10.1007/s12185-009-0298-1
[15] Petersdorf, S., Kopecky, K., Stuart, R.K., Larson, R.A., Nevill, T.J., Stenke, L., Slovak, M.L., Tallman, M.S., Willman, C.L., Erba, H. and Appelbaum, F.R. (2009) Preliminary results of Southwest Oncology Group Study S0106: An international intergroup phase 3 randomized trial comparing the addition of gemtuzumab ozogamicin to standard induction therapy versus standard induction therapy followed by a second randomization to post-consolidation gemtuzumab ozogamicin versus no additional therapy for previously untreated acute myeloid leukemia. Blood, 114, (abstr 790).
[16] Burnett, A.K., Hills, R.K., Milligan, D., Kjeldsen, L., Kell, J., Russell, N.H., Yin, J.A., Hunter, A., Goldstone, A.H. and Wheatley, K. (2011) Identification of patients with acute myeloblastic leukemia who benefit from the addition of gemtuzumab ozogamicin: Results of the MRC AML15 trial. Journal of Clinical Oncology, 29, 369-377. doi:10.1200/JCO.2010.31.4310
[17] Burnett, A.K., Russell, N.H., Hills, R.K., Kell, J., Freeman, S., Kjeldsen, L., Hunter, A.E., Yin, J., Craddock, C.F., Dufva, I.H., Wheatley, K. and Miligan, D. (2012) Addition of gemtuzumab ozogamicin to induction chemotherapy improves survival in older patients with acute myeloid leukemia. Journal of Clinical Oncology, 30, 3924-3931. doi:10.1200/JCO.2012.42.2964
[18] Castaigne, S., Pautas, C., Terre, C., Raffoux, E., Bordessoule, D., Bastie, J.N., Legrand, O., Thomas, X., Turlure, P., Reman, O., de Revel, T., Gastaud, L., de Gunzburg, N., Contentin, N., Henry, E., Marolleau, J.P., Aljijakli, A., Rousselot, P., Fenaux, P., Preudhomme, C., Chevret, S., Dombret, H. and Acute Leukemia French Association. (2012) Effect of gemtuzumab ozogamicin on survival of adult patients with de-novo acute myeloid leukaemia (ALFA-0701): A randomised, open-label, phase 3 study. Lancet, 379, 1508-1516. doi:10.1016/S0140-6736(12)60485-1
[19] Sievers, E.L., Appelbaum, F.R., Spielberger, R.T., Forman, S.J., Flowers, D., Smith, F.O., Shannon-Dorcy, K., Berger, M.S. and Bernstein, I.D. (1999) Selective ablation of acute myeloid leukemia using antibody-targeted chemotherapy: A phase I study of an anti-CD33 calicheamicin immunoconjugate. Blood, 93, 3678-3684.
[20] Bross, P.F., Beitz, J., Chen, G., Chen, X.H., Duffy, E., Kieffer, L., Roy, S., Sridhara, R., Rahman, A., Williams, G. and Pazdur, R. (2001) Approval summary: Gemtuzumab ozogamicin in relapsed acute myeloid leukemia. Clinical Cancer Research, 7, 1490-1496.
[21] Taksin, A.L., Legrand, O., Raffoux, E., de Revel, T., Thomas, X., Contentin, N., Bouabdallah, R., Pautas, C., Turlure, P., Reman, O., Gardin, C., Varet, B., de Botton, S., Pousset, F., Farhat, H., Chevret, S., Dombret, H. and Castaigne, S. (2007) High efficacy and safety profile of fractionated doses of Mylotarg as induction therapy in patients with relapsed acute myeloblastic leukemia: A prospective study of the alfa group. Leukemia, 21, 66-71. doi:10.1038/sj.leu.2404434
[22] Piccaluga, P.P., Martinelli, G., Rondoni, M., Malagola, M., Gaitani, S., Isidori, A., Bonini, A., Gugliotta, L., Luppi, M., Morselli, M., Sparaventi, G., Visani, G. and Baccarani, M. (2004) Gemtuzumab ozogamicin for relapsed and refractory acute myeloid leukemia and myeloid sarcomas. Leuk Lymphoma, 45, 1791-1795. doi:10.1080/1042819042000219485
[23] Amadori, S., Suciu, S., Selleslag, D., Stasi, R., Alimena, G., Baila, L., Rizzoli, V., Borlenghi, E., Gaidano, G., Magro, D., Torelli, G., Muus, P., Venditti, A., Cacciola, E., Lauria, F., Vignetti, M. and de Witte, T. (2010) Randomized trial of two schedules of low-dose gemtuzumab ozogamicin as induction monotherapy for newly diagnosed acute myeloid leukaemia in older patients not considered candidates for intensive chemotherapy. A phase II study of the EORTC and GIMEMA leukaemia groups (AML-19). British Journal of Haematology, 149, 376-382. doi:10.1111/j.1365-2141.2010.08095.x
[24] Amadori, S., Suciu, S., Stasi, R., Willemze, R., Mandelli, F., Selleslag, D., Denzlinger, C., Muus, P., Stauder, R., Berneman, Z., Pruijt, J., Nobile, F., Cassibba, V., Marie, J.P., Beel-dens, F., Baila, L., Vignetti, M. and de Witte, T. (2005) Gemtuzumab ozogamicin (Mylotarg) as single-agent treatment for frail patients 61 years of age and older with acute myeloid leukemia: final results of AML-15B, a phase 2 study of the European Organisation for Research and Treatment of Cancer and Gruppo Italiano Malattie Ematologiche dell’Adulto Leukemia Groups. Leukemia, 19, 1768-1773. doi:10.1038/sj.leu.2403901
[25] Nabhan, C., Rundhaugen, L.M., Riley, M.B., Rademaker, A., Boehlke, L., Jatoi, M. and Tallman, M.S. (2005) Phase II pilot trial of gemtuzumab ozogamicin (GO) as first line therapy in acute myeloid leukemia patients age 65 or older. Leukemia Research, 29, 53-57. doi:10.1016/j.leukres.2004.04.011
[26] Rajvanshi, P., Shulman, H.M., Sievers, E.L. and McDonald, G.B. (2002) Hepatic sinusoidal obstruction after gemtuzumab ozogamicin (Mylotarg) therapy. Blood, 99, 2310-2314. doi:10.1182/blood.V99.7.2310
[27] Delaunay, J., Recher, C., Pigneux, A., Witz, F., Vey, N., Blanchet, O., Lefebvre, P., Luquet, I., Guillerme, I., Volteau, C., Gyan, E., Lioure, B., Jourdan, E., Bouscary, D., Guieze, R., Randriamalala, E., Uribe, M.E.O., Dreyfus, F., Lacombe, C., Béné, Mc., Cahn, J.Y., Harousseau, J.C. and Ifrah, N. (2011) Addition of gemtuzumab ozogamycin to chemotherapy improves event-free survival but not overall survival of AML patients with intermediate cytogenetics not eligible for allogeneic transplantation. Results of the GOELAMS AML 2006 IR study. Blood, 118, 79.
[28] Fernandez, H.F., Sun, Z., Litzow, M.R., Luger, S.M., Paietta, E.M., Racevskis, J., Dewald, G., Ketterling, R.P., Rowe, J.M., Lazarus, H.M. and Tallman, M.S. (2011) Autologous transplantation gives encouraging results for young adults with favorable-risk acute myeloid leukemia, but is not improved with gemtuzumab ozogamicin. Blood, 117, 5306-5613. doi:10.1182/blood-2010-09-309229
[29] Lowenberg, B., Beck, J., Graux, C., van Putten, W., Schouten, H.C., Verdonck, L.F., Ferrant, A., Sonneveld, P., Jongen-Lavrencic, M., von Lilienfeld-Toal, M., Biemond, B.J., Vellenga, E., Breems, D., de Muijnck, H., Schaafsma, R., Verhoef, G., Döhner, H., Gratwohl, A., Pabst, T., Ossenkoppele, G.J., Maertens, J., Dutch-Belgian Hemato-Oncology Cooperative Group (HOVON), German Austrian AML Study Group (AMLSG) and Swiss Group for Clinical Cancer Research Collaborative Group (SAKK). (2010) Gemtuzumab ozogamicin as postremission treatment in AML at 60 years of age or more: results of a multicenter phase 3 study. Blood, 115, 2586-2591. doi:10.1182/blood-2009-10-246470
[30] Lambert, J., Jerome Lambert, J., Olivier Nibourel, O., Pautas, C., Hayette, S., Cayuela, J.M., Terre, C., Rousselot, P., Dombret, H., Preudhomme, C., Castaigne, S. and Renneville, A. (2012) Minimal residual disease assessed by WT1 expression and NPM1 mutations specific RQ-PCR assays identifies patients with distinct outcomes in the ALFA 0701 trial and is decreased by treatment with Gemtuzumab Ozogamicin. Blood, 120, 659.
[31] Cortes, J., Tsimberidou, A.M., Alvarez, R., Thomas, D., Beran, M., Kantarjian, H., Estey, E. and Giles, F.J. (2002) Mylotarg combined with topotecan and cytarabine in patients with refractory acute myelogenous leukemia. Cancer Chemotherapy Pharmacology, 50, 497-500. doi:10.1007/s00280-002-0539-y
[32] Alvarado, Y., Tsimberidou, A., Kantarjian, H., Cortes, J., Garcia-Manero, G., Faderl, S., Thomas, D., Estey, E. and Giles, F.J. (2003) Pilot study of mylotarg, idarubicin and cytarabine combination regimen in patients with primary resistant or relapsed acute myeloid leukemia. Cancer Chemotherapy Pharmacology, 51, 87-90. doi:10.1007/s00280-002-0546-z
[33] Tsimberidou, A., Cortes, J., Thomas, D., Garcia-Manero, G., Verstovsek, S., Faderl, S., Albitar, M., Kantarjian, H., Estey, E. and Giles, F.J. (2003) Gemtuzumab ozogamicin, fludarabine, cytarabine and cyclosporine combination regimen in patients with CD33+ primary resistant or relapsed acute myeloid leukemia. Leukemia Research, 27, 893-897. doi:10.1016/S0145-2126(03)00022-5
[34] Specchia, G., Pastore, D., Carluccio, P., Spinosa, G., Giannoccaro, M., Rizzi, R., Mestice, A. and Liso, V. (2007) Gemtuzumab ozogamicin with cytarabine and mitoxantrone as a third-line treatment in a poor prognosis group of adult acute myeloid leukemia patients: A single-center experience. Annals of Hematology, 86, 425-428. doi:10.1007/s00277-007-0272-z
[35] Chevallier, P., Delaunay, J., Turlure, P., Pigneux, A., Hunault, M., Garand, R., Guillaume, T., Avet-Loiseau, H., Dmytruk, N., Girault, S., Milpied, N., Ifrah, N., Mohty, M. and Harousseau, J.L. (2008) Long-term disease-free survival after gemtuzumab, intermediate-dose cytarabine, and mitoxantrone in patients with CD33(+) primary resistant or relapsed acute myeloid leukemia. Journal of Clinical Oncology, 26, 5192-5197. doi:10.1200/JCO.2007.15.9764
[36] Schlenk, R.F., Dohner, K., Jürgen Krauter, J., Späth, D., Valle, F., Heydrich, B., Horst, H.A., Schmidt-Wolf, I., Rummel, A., Götze, K., Koller, E., Petzer, A., Mergenthaler, H.G., Salwender, H., Fiedler, W., Kirchen, H., Haase, D., Krämers, S., Theobald, A., Matzdorff, A.C., Ganser, A., Döhner, H. (2007) All-Trans retinoic acid and gemtuzumab ozogamicin as adjunct to high-Dose cytarabine-Based salvage therapy in primary refractory acute myeloid leukemia: Results of AMLSG 05-04 trial. Blood, 110.
[37] Fianchi, L., Pagano, L., Leoni, F., Storti, S., Voso, M.T., Valentini, C.G., Rutella, S., Scardocci, A., Caira, M., Gianfaldoni, G. and Leone, G. (2008) Gemtuzumab ozogamicin, cytosine arabinoside, G-CSF combination (G-AraMy) in the treatment of elderly patients with poor-prognosis acute myeloid leukemia. Annals of Oncology, 19, 128-134. doi:10.1093/annonc/mdm451
[38] Martin, M.G., Augustin, K.M., Uy, G.L., Welch, J.S., Hladnik, L., Goyal, S., Tiwari, D., Monahan, R.S., Reichley, R.M., Cashen, A.F., Stockerl-Goldstein, K., Westervelt, P., Abboud, C.N., Dipersio, J.F. and Vij, R. (2009) Alvage therapy for acute myeloid leukemia with fludarabine, cytarabine, and idarubicin with or without gemtuzumab ozogamicin and with concurrent or sequential GCSF. American Journal of Hematology, 84, 733-737. doi:10.1002/ajh.21545
[39] Ritzow, M.R., Othus, M., Cripe, L.D., Gore, S.D., Lazarus, H.M., Lee, S.J., Bennett, J.M., Paietta, E.M., Dewald, G.W., Rowe, J.M. and Tallman, M.S. (2010) Failure of three novel regimens to improve outcome for patients with relapsed or refractory acute myeloid leukaemia: A report from the Eastern Cooperative Oncology Group. British Journal of Haematology, 148, 217-225. doi:10.1111/j.1365-2141.2009.07917.x
[40] Stone, R.M., Moser, B., Sanford, B., Schulman, P., Kolitz, J.E., Allen, S., Stock, W., Galinsky, I., Vij, R., Marcucci, G., Hurd, D. and Larson, R.A. (2011) High dose cytarabine plus gemtuzumab ozogamicin for patients with relapsed or refractory acute myeloid leukemia: Cancer and Leukemia Group B study 19902. Leukemia Research, 35, 329-333. doi:10.1016/j.leukres.2010.07.017
[41] Prebet, T., Etienne, A., Devillier, R., Romeo, E., Charbonnier, A., D’Incan, E., Esterni, B., Arnoulet, C., Blaise, D. and Vey, N. (2011) Improved outcome of patients with low- and intermediate-risk cytogenetics acute myeloid leukemia (AML) in first relapse with gemtuzumab and cytarabine versus cytarabine: Results of a retrospective comparative study. Cancer, 117, 974-981. doi:10.1002/cncr.25554
[42] Farhat, H., Reman, O., Raffoux, E., Berthon, C., Pautas, C., Kammoun, L., Chantepie, S., Gardin, C., Rousselot, P., Chevret, S., Dombret, H. and Castaigne, S. (2012) Fractionated doses of gemtuzumab ozogamicin with escalated doses of daunorubicin and cytarabine as first acute myeloid leukemia salvage in patients aged 50- 70-year old: A phase 1/2 study of the acute leukemia French association. American Journal of Hematology, 87, 62-65. doi:10.1002/ajh.22201
[43] Chevallier, P., Prebet, T., Pigneux, A., Hunault, M., Delaunay, J., Perry, F., Lode, L., Richebourg, S., Blanchet, O., Vey, N., Ifrah, N., Milpied, N., Blaise, D., Harousseau, J.L. and Mohty, M. (2010) Influence of NPM1 and FLT3- ITD status on outcome in relapsed/refractory AML patients receiving salvage therapy including gemtuzumab ozogamicin. Leukemia, 24, 467-469. doi:10.1038/leu.2009.214
[44] Walter, R.B., Medeiros, B.C., Powell, B.L., Schiffer, C.A., Appelbaum, F.R. and Estey, E.H. (2012) Phase II trial of vorinostat and gemtuzumab ozogamicin as induction and post-remission therapy in older adults with previously untreated acute myeloid leukemia. Haematologica, 97, 739-742. doi:10.3324/haematol.2011.055822
[45] Nand, S., Megan Othus, M., John, E., Godwin, J.E., Willman, C.L., Norwood, T., Erba, H.P., Howard, D., Coutre, S.E. and Appelbaum, F.R. (2012) A Phase II Trial of Azacitidine (NSC-102816) and Gemtuzumab Ozogamicin (NSC-720568) As Induction and Post-Remission Therapy in Patients of Age 60 and Older with Previously Untreated Non-M3 Acute Myeloid Leukemia (SWOG S0703): Report On the Poor Risk Patients. Blood, 120.
[46] Daver, N., Kantarjian, H.M., Garcia-Manero, G., GarciaManero, G., Konopleva, Z.E.M., Burger, J.A., O’Brien, S., Ferrajoli, A., Verstovsek, S., Kadia, T.M., Jabbour, E.J., Faderl, S., Diaz-Pines-Mateo, M., Pemmaraju, N., Pierce, S.A., Cortes, J.E. and Borthakur, G. (2012) Decitabine and gemtuzumab ozogamicin in acute myelogenous leukemia and high-risk myelodysplastic syndrome. Blood, 120.
[47] Lo Coco, F., Ammatuna, E. and Noguera, N. (2006) Treatment of acute promyelocytic leukemia with gemtuzumab ozogamicin. Clinical Advances in Hematology and Oncology, 4, 57-62, 76-77.
[48] Takeshita, A., Shinjo, K., Naito, K., Matsui, H., Sahara, N., Shigeno, K., Horii, T., Shirai, N., Maekawa, M., Ohnishi, K., Naoe, T. and Ohno, R. (2005) Efficacy of gemtuzumab ozogamicin on ATRA- and arsenic-resistant acute promyelocytic leukemia (APL) cells. Leukemia, 19, 1306-1311. doi:10.1038/sj.leu.2403807
[49] Candoni, A., Damiani, D., Michelutti, A., Masolini, P., Michieli, M., Michelutti, T., Geromin, A. and Fanin, R. (2003) Clinical characteristics, prognostic factors and multidrug-resistance related protein expression in 36 adult patients with acute promyelocytic leukemia. European Journal of Haematology, 71, 1-8. doi:10.1034/j.1600-0609.2003.00084.x
[50] Lo-Coco, F., Cimino, G., Breccia, M., Noguera, N.I., Diverio, D., Finolezzi, E., Pogliani, E.M., Di Bona, E., Micalizzi, C., Kropp, M., Venditti, A., Tafuri, A. and Mandelli, F. (2004) Gemtuzumab ozogamicin (Mylotarg) as a single agent for molecularly relapsed acute promyelocytic leukemia. Blood, 104, 1995-1999. doi:10.1182/blood-2004-04-1550
[51] Ravandi, F., Estey, E., Jones, D., Faderl, S., O’Brien, S., Fiorentino, J., Pierce, S., Blamble, D., Estrov, Z., Wierda, W., Ferrajoli, A., Verstovsek, S., Garcia-Manero, G., Cortes, J. and Kantarjian, H. (2009) Effective treatment of acute promyelocytic leukemia with all-trans-retinoic acid, arsenic trioxide, and gemtuzumab ozogamicin. Journal of Clinical Oncology, 27, 504-510. doi:10.1200/JCO.2008.18.6130
[52] Aribi, A., Kantarjian, H.M., Estey, E.H., Koller, C.A., Thomas, D.A., Kornblau, S.M., Faderl, S.H., Laddie, N.M., Garcia-Manero, G. and Cortes, J.E. (2007) Combination therapy with arsenic trioxide, all-trans retinoic acid, and gemtuzumab ozogamicin in recurrent acute promyelocytic leukemia. Cancer, 109, 1355-1359. doi:10.1002/cncr.22524

comments powered by Disqus

Copyright © 2014 by authors and Scientific Research Publishing Inc.

Creative Commons License

This work and the related PDF file are licensed under a Creative Commons Attribution 4.0 International License.